Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical benefit in patients with resectable NSCLC

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC

LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC

Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC